Trial Search Results
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC).
Secondary objectives: To evaluate the change in Alkaline Phosphatase (ALP) from baseline to 6 months post-treatment following treatment with hymecromone plus standard of care compared with standard of care.
To evaluate changes in biomarkers of PSC disease during hymecromone treatment, namely: (a) fibrotic effect (FibroScan); (b) inflammatory biomarkers (serum Hyaluronan (HA)); and, (c) T-cell count.
Stanford is currently not accepting patients for this trial.
- Drug: Hymecromone
- Diagnosis of primary sclerosing cholangitis confirmed by liver biopsy and/or imaging
- If history of endoscopically confirmed inflammatory bowel disease, currently stable
based on Mayo Score / Disease Activity Index (DAI) for Ulcerative Colitis Score ≤ 1,
normal inflammatory markers (ESR, CRP and fecal calprotectin) and stable non-excluded
medical therapy for at least 6 months
- Currently receiving biologic therapies
- Known allergy to hymecromone
- Serious liver disease
Ages Eligible for Study
14 Years - 75 Years
Genders Eligible for Study